243 related articles for article (PubMed ID: 8212422)
21. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
22. Therapy of superficial bladder cancer.
Nseyo UO; Lamm DL
Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
[TBL] [Abstract][Full Text] [Related]
23. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
24. [Clinical experience with BCG immune prevention in superficial bladder cancer].
Bach D; Romics I; Rüssel C
Urologe A; 1992 Sep; 31(5):296-301. PubMed ID: 1302409
[TBL] [Abstract][Full Text] [Related]
25. Intravesical treatment of bladder cancer: current problems and needs.
Schmitz-Dräger BJ; Müller M
Urol Int; 1998; 61(4):199-205. PubMed ID: 10419409
[TBL] [Abstract][Full Text] [Related]
26. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
27. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
Bunimovich-Mendrazitsky S; Byrne H; Stone L
Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic strategies for high-risk bladder cancer.
Sharma P; Old LJ; Allison JP
Semin Oncol; 2007 Apr; 34(2):165-72. PubMed ID: 17382800
[TBL] [Abstract][Full Text] [Related]
29. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
30. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
31. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
32. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
33. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
34. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
35. Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
Jauhiainen KE; Alfthan OS
Scand J Urol Nephrol Suppl; 1991; 138():179-85. PubMed ID: 1785001
[TBL] [Abstract][Full Text] [Related]
36. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
37. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.
Lamm DL; DeHaven JI; Riggs DR; Delgra C; Burrell R
Urol Res; 1993 Jan; 21(1):33-7. PubMed ID: 8456536
[TBL] [Abstract][Full Text] [Related]
38. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
[No Abstract] [Full Text] [Related]
39. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy.
Riggs DR; Tarry WF; DeHaven JI; Sosnowski J; Lamm DL
J Urol; 1992 Jan; 147(1):212-4. PubMed ID: 1729535
[TBL] [Abstract][Full Text] [Related]
40. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
